The University of Pretoria has been a leading member of the Eastern Cooperative Oncology Group (ECOG) since 1972. This application requests the support necessary for continued participation in ECOG by the University of Pretoria. As a member of ECOG, this institution is attempting to improve both the quality and duration of cancer patients lives by developing and scientifically evaluating the most effective treatment programs for all types and stages of cancer.
The specific aims of this proposal include: 1. To maintain a high accrual rate of fully evaluable patients on all ECOG therapeutic and non-therapeutic protocols. 2. To maintain and refine an effective data management program. In November 1991, the ECOG Statistical Center Award for Excellence in Data Management was awarded to the University of Pretoria for achieving the highest score in the evaluation of the quality of data submitted to the ECOG Statistical Center by participating institutions. 3. Continued contribution to the development of innovative treatment protocols and continued leadership in the scientific programs of ECOG. Investigators in Pretoria chair or have chaired numerous ECOG studies in various disease areas. These include malignant melanoma (EST 3690), breast cancer (EST 2177, EST 1179, EST 2181, EST 4181), primary liver cancer (EST 2273, EST 1280, EST 2282), mesothelioma (EST P-A 380, EST P-A 783, EST 1786) and esophagus cancer (EST 2287). Investigators from Pretoria are co-chairmen on numerous ECOG studies. The principal investigator served as Chairman of the Breast Cancer Committee of ECOG 1981-1982 and Pretoria continues to be a major resource for clinical trials in Breast Cancer. 4. To publish results of ECOG studies. G Falkson was chairman of the Breast Cancer Data Base Review Committee of ECOG from 1983 - 1990. Since the last application for a PHS Grant Pretoria doctors have been authors of 71 publications resulting from ECOG studies of which they were first authors in 19 publications. 5. To continue to present the scientific information gathered by ECOG at national and international meetings. 6. To contribute to ECOG and NCI programs on hepatocellular carcinoma, esophagus cancer, and mesothelioma where Pretoria has unique resources as evidence by the work done so far.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA059307-01
Application #
3559037
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-05-05
Project End
1994-06-30
Budget Start
1993-05-05
Budget End
1994-06-30
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pretoria
Department
Type
DUNS #
City
Pretoria
State
Country
South Africa
Zip Code
0002
Wolff, Antonio C; Wang, Molin; Li, Hailun et al. (2010) Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 121:111-20
Kyle, Robert A; Jacobus, Susanna; Friedenberg, William R et al. (2009) The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Cancer 115:2155-64
Flinn, Ian W; Neuberg, Donna S; Grever, Michael R et al. (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-8
Messing, Edward M; Manola, Judith; Yao, Jorge et al. (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-9
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
Okuno, Scott; Ryan, Louise M; Edmonson, John H et al. (2003) Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97:1969-73
Obasaju, C; Manola, J; Hudes, G R et al. (2001) Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. Am J Clin Oncol 24:150-4
Giantonio, B J; Hochster, H; Blum, R et al. (2001) Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs 19:89-92
Leaf, A N; Wolf, B C; Kirkwood, J M et al. (2000) Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol 17:47-51
Simpson, J F; Gray, R; Dressler, L G et al. (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059-69